中樑控股(02772.HK)擬發行2億美元優先票據
格隆匯 10 月 22日丨中樑控股(02772.HK)發佈公告,2020年10月21日,公司連同附屬公司擔保人就發行2億美元於2022年到期的9.5%優先票據與國泰君安國際、瑞銀、中銀國際、信銀國際、建銀國際、招銀國際、瑞信、德意志銀行、渣打銀行、交銀國際及萬盛金融控股有限公司訂立購買協議。
公司將尋求票據在聯交所上市,並已獲聯交所發出有關票據符合資格上市的確認書,表示票據可按發售備忘錄所述,以僅向專業投資者進行債務證券發行的方式上市。公司計劃將發行票據所得款項淨額用作現有債務再融資。公司可能會因應持續轉變的市況調整其計劃,並因而重新分配所得款項淨額的用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.